Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Drugs

• Publication date

  2018-02-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s40265-018-0865-yPMID 29396834
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients with Stable Angina (S32.004)

  2018cited by this paper
• Primary Results of PROMISE-1 (Prevention Of Migraine via Intravenous eptinezumab Safety and Efficacy–1) Trial: a Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Eptinezumab for Prevention of Frequent Episodic Migraines (S20.001)

  2018cited by this paper
• PACAP38: Emerging Drug Target in Migraine and Cluster Headache

  2017cited by this paper
• Oxytocin and Migraine Headache

  2017cited by this paper
• Erenumab (AMG 334) in episodic migraine

  2017cited by this paper
• Sex differences in the epidemiology, clinical features, and pathophysiology of migraine.

  2017cited by this paper
• Possible Involvement of the CACNA1E Gene in Migraine: A Search for Single Nucleotide Polymorphism in Different Clinical Phenotypes

  2017cited by this paper
• Pathophysiology of Migraine: A Disorder of Sensory Processing.

  2017cited by this paper
• A Controlled Trial of Erenumab for Episodic Migraine

  2017cited by this paper
• Fremanezumab as Add‐On Treatment for Patients Treated With Other Migraine Preventive Medicines

  2017cited by this paper
• Fremanezumab for the Preventive Treatment of Chronic Migraine

  2017cited by this paper
• Association between peripheral nerve function and structure in human diabetic nerves

  2017cited by this paper
• Intact blood−brain barrier during spontaneous attacks of migraine without aura: a 3T DCE‐MRI study

  2017cited by this paper
• Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

  2017cited by this paper
• Efficacy of erenumab in subjects with episodic migraine with prior preventive treatment failure(s)

  2017cited by this paper
• Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial

  2017cited by this paper
• Kappa opioid receptor antagonists: A possible new class of therapeutics for migraine prevention

  2017cited by this paper
• Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.

  2017cited by this paper
• Increased brainstem perfusion, but no blood-brain barrier disruption, during attacks of migraine with aura

  2017cited by this paper
• Migraine: What Imaging Reveals

  2016cited by this paper
• Transcranial magnetic stimulation and potential cortical and trigeminothalamic mechanisms in migraine

  2016cited by this paper
• Impact of Migraine on the Family: Perspectives of People With Migraine and Their Spouse/Domestic Partner in the CaMEO Study.

  2016cited by this paper
• Type II Turn of Receptor-bound Salmon Calcitonin Revealed by X-ray Crystallography*

  2016cited by this paper
• Ictal lack of binding to brain parenchyma suggests integrity of the blood–brain barrier for 11 C-dihydroergotamine during glyceryl trinitrate-induced migraine

  2016cited by this paper
• Metabotropic glutamate receptor 5: a target for migraine therapy

  2016cited by this paper
• The migraine postdrome

  2016cited by this paper
• Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial.

  2016cited by this paper
• The migraine generator revisited: continuous scanning of the migraine cycle over 30 days and three spontaneous attacks.

  2016cited by this paper
• Wiping Out CGRP: Potential Cardiovascular Risks.

  2016cited by this paper
• TEV-48125 for the preventive treatment of chronic migraine

  2016cited by this paper
• A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine

  2016cited by this paper
• A double-blind, randomized, placebo-controlled pilot trial to determine the efficacy and safety of ibudilast, a potential glial attenuator, in chronic migraine

  2016cited by this paper
• Premonitory and nonheadache symptoms induced by CGRP and PACAP38 in patients with migraine

  2016cited by this paper
• Immunohistochemical localization of the calcitonin gene-related peptide binding site in the primate trigeminovascular system using functional antagonist antibodies.

  2016cited by this paper
• No Change in Interictal PACAP Levels in Peripheral Blood in Women With Chronic Migraine

  2016cited by this paper
• Oxytocin receptor: Expression in the trigeminal nociceptive system and potential role in the treatment of headache disorders

  2016cited by this paper
• Memantine for Prophylactic Treatment of Migraine Without Aura: A Randomized Double‐Blind Placebo‐Controlled Study

  2016cited by this paper
• Bench to bedside advances in the 21st century for primary headache disorders: migraine treatments for migraine patients.

  2016cited by this paper
• Genetic insights into migraine and glutamate: a protagonist driving the headache.

  2016cited by this paper
• Moulton EA, Becerra L, Johnson A, Burstein R, Borsook D. Altered hypothalamic functional connectivity with autonomic circuits and the locus coeruleus in migraine. PLoS One. 2014;9: e95508

  2015cited by this paper
• O028. Thalamo-cortical network changes during the migraine cycle: insights from MRI-based microstructural and functional resting-state network correlation analysis

  2015cited by this paper
• CGRP Mechanism Antagonists and Migraine Management

  2015cited by this paper
• Adherence to oral migraine-preventive medications among patients with chronic migraine

  2015cited by this paper
• New players in the preventive treatment of migraine

  2015cited by this paper
• Glial Attenuation With Ibudilast in the Treatment of Medication Overuse Headache: A Double‐Blind, Randomized, Placebo‐Controlled Pilot Trial of Efficacy and Safety

  2015cited by this paper
• CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment.

  2015cited by this paper
• Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium

  2015cited by this paper
• Pharmacological Trials in Migraine: It's Time to Reappraise Where the Headache Is and What the Pain Is Like

  2015cited by this paper
• Critical evaluation of three hemodynamic models for the numerical simulation of intra-stent flows.

  2015cited by this paper
• Migraine pathophysiology: lessons from mouse models and human genetics.

  2015cited by this paper
• The Journey to Establish CGRP as a Migraine Target: A Retrospective View

  2015cited by this paper
• Migraine: Multiple Processes, Complex Pathophysiology

  2015cited by this paper
• Triptan-induced disruption of trigemino-cortical connectivity

  2015cited by this paper
• Evidence for orexinergic mechanisms in migraine.

  2015cited by this paper
• Evaluation of the impact of neutralizing antibodies on IFNβ response.

  2015cited by this paper
• Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.

  2015cited by this paper
• OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine

  2015cited by this paper
• Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.

  2015cited by this paper
• Therapeutic Monoclonal Antibodies: What Headache Specialists Need to Know

  2015cited by this paper
• The thalamic reticular nucleus is activated by cortical spreading depression in freely moving rats: prevention by acute valproate administration

  2015cited by this paper
• Periaqueductal gray calcitonin gene-related peptide modulates trigeminovascular neurons

  2015cited by this paper
• Neuronal PAC1 receptors mediate delayed activation and sensitization of trigeminocervical neurons: Relevance to migraine

  2015cited by this paper
• A second trigeminal CGRP receptor: function and expression of the AMY1 receptor

  2015cited by this paper
• α-Calcitonin gene related peptide (α-CGRP) mediated lipid mobilization in 3T3-L1 adipocytes.

  2014cited by this paper
• An Exploratory Study of Salivary Calcitonin Gene‐Related Peptide Levels Relative to Acute Interventions and Preventative Treatment With OnabotulinumtoxinA in Chronic Migraine

  2014cited by this paper
• PACAP-38 but not VIP induces release of CGRP from trigeminal nucleus caudalis via a receptor distinct from the PAC1 receptor.

  2014cited by this paper
• Memantine for the Prevention of Primary Headache Disorders

  2014cited by this paper
• Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks.

  2014cited by this paper
• Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38.

  2014cited by this paper
• Neurochemical Pathways That Converge on Thalamic Trigeminovascular Neurons: Potential Substrate for Modulation of Migraine by Sleep, Food Intake, Stress and Anxiety

  2014cited by this paper
• Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study.

  2014cited by this paper
• Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.

  2014cited by this paper
• CGRP and VIP Levels as Predictors of Efficacy of Onabotulinumtoxin Type A in Chronic Migraine

  2014cited by this paper
• New Targets for Migraine Therapy

  2014cited by this paper
• Pituitary adenylate cyclase activating polypeptide and migraine

  2014cited by this paper
• Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program

  2014cited by this paper
• BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial

  2014cited by this paper
• Altered Hypothalamic Functional Connectivity with Autonomic Circuits and the Locus Coeruleus in Migraine

  2014cited by this paper
• Monoclonal Antibodies for Migraine: Preventing Calcitonin Gene-Related Peptide Activity

  2014cited by this paper
• Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial.

  2014cited by this paper
• Calcitonin gene-related peptide: physiology and pathophysiology.

  2014cited by this paper
• Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention

  2014cited by this paper
• Migraine: a brain state.

  2013cited by this paper
• Why Does Sleep Stop Migraine?

  2013cited by this paper
• The International Classification of Headache Disorders, 3rd edition (beta version)

  2013cited by this paper
• Bilateral Descending Hypothalamic Projections to the Spinal Trigeminal Nucleus Caudalis in Rats

  2013cited by this paper
• Hypothalamic and basal ganglia projections to the posterior thalamus: possible role in modulation of migraine headache and photophobia.

  2013cited by this paper
• Preventive Pharmacologic Treatments for Episodic Migraine in Adults

  2013cited by this paper
• Paraventricular Hypothalamic Regulation of Trigeminovascular Mechanisms Involved in Headaches

  2013cited by this paper
• Role of kappa-opioid receptors in stress and anxiety-related behavior

  2013cited by this paper
• Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional study.

  2013cited by this paper
• Recent progress in migraine pathophysiology: role of cortical spreading depression and magnetic resonance imaging

  2013cited by this paper
• Calcitonin Gene‐Related Peptide (CGRP) and Migraine Current Understanding and State of Development

  2013cited by this paper
• Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults

  2012cited by this paper
• Orexin receptors as therapeutic drug targets.

  2012cited by this paper
• Postpartum migraines: a long-term prospective study.

  2012cited by this paper
• A translational in vivo model of trigeminal autonomic cephalalgias – therapeutic characterization with brainstem stimulation

  2012cited by this paper
• Orexin Receptor Antagonism, a New Sleep-Enabling Paradigm: A Proof-of-Concept Clinical Trial

  2012cited by this paper
• The 2012 AHS/AAN Guidelines for Prevention of Episodic Migraine: A Summary and Comparison With Other Recent Clinical Practice Guidelines

  2012cited by this paper
• Acid‐sensing ion channel 1: A novel therapeutic target for migraine with aura

  2012cited by this paper

• Treating episodic migraine with precision: the evolving landscape of targeted therapies driven by insights in disease biology

  2025cites this paper
• Triple network disruption in medication overuse headache: functional signatures and clinical impact

  2025cites this paper
• Migraine treatment: quo vadis? Real-world data study (2015–2022) in Spain

  2024cites this paper
• Remote electrical neuromodulation for migraine prevention: A double‐blind, randomized, placebo‐controlled clinical trial

  2023cites this paper
• Approach to headache disorders and the management of migraine: consensus guidelines from the Headache Society of Singapore, first edition (2023).

  2023cites this paper
• Temporal analysis of remote electric neuromodulation for the prevention of migraine.

  2023cites this paper
• Botulinum toxin A for refractory neuropathic pain in supraorbital postherpetic neuralgia

  2023cites this paper
• Headaches in Pregnancy and Postpartum: ACOG Clinical Practice Guideline No. 3.

  2022cites this paper
• Eptinezumab-jjmr, a humanized monoclonal specific to Calcitonin Gene Related Peptide, for the preventive treatment of migraine in adults.

  2022cites this paper
• Rimegepant for the treatment of migraine.

  2022cites this paper
• HCN2 Ion Channels Drive Pain in Rodent Models of Migraine

  2022cites this paper
• A Comprehensive Review of Celecoxib Oral Solution for the Acute Treatment of Migraine.

  2022cites this paper
• A Comprehensive Review of Zavegepant as Abortive Treatment for Migraine.

  2022cites this paper
• Myocardial infarction, stroke and cardiovascular mortality among migraine patients: a systematic review and meta-analysis

  2022cites this paper
• TRIGGER FACTORS ASSOCIATED WITH MIGRAINE HEADACHE AMONG NORTHERN IRANIAN POPULATION

  2021cites this paper
• Cannabinoid Use in a Tertiary Headache Clinic: A Cross-Sectional Survey

  2021cites this paper
• Was it something I ate? Understanding the bidirectional interaction of migraine and appetite neural circuits.

  2021cites this paper
• Translation and validation of an extended German version of ID Migraine™ as a migraine screening tool

  2020cites this paper
• Acid‐sensing ion channel 3 blockade inhibits durovascular and nitric oxide‐mediated trigeminal pain

  2020cites this paper
• White Matter Diseases: An Update for Neurologists

  2020cites this paper
• Economic burden of migraine in Singapore

  2020cites this paper
• Enhanced mindfulness based stress reduction (MBSR+) in episodic migraine: a randomized clinical trial with MRI outcomes.

  2020cites this paper
• Emerging Treatment Options for Migraine.

  2020cites this paper
• Galcanezumab: A Review in the Prevention of Migraine and Treatment of Episodic Cluster Headache

  2020cites this paper
• Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience

  2020cites this paper
• Treatment and management of migraine in neurological ambulatory practice in Poland by indicating therapy with monoclonal anti-CGRP antibodies.

  2020cites this paper
• The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response

  2020cites this paper
• Safety and efficacy of galcanezumab in Taiwanese patients: a post-hoc analysis of phase 3 studies in episodic and chronic migraine

  2020cites this paper
• Migraine Pathophysiology.

  2020cites this paper
• An Evidence-Based Review of Galcanezumab for the Treatment of Migraine

  2020cites this paper
• Treatment patterns and medication adherence among newly diagnosed patients with migraine: a drug utilisation study

  2020cites this paper
• A 40-Year-Old Woman with Chronic Recurrent Headache (Migraine)

  2020cites this paper
• Lasmiditan for the Treatment of Migraines With or Without Aura in Adults.

  2020cites this paper
• Migraine

  2020cites this paper
• Postconcussive Headache

  2020cites this paper
• Migräne

  2020cites this paper
• Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis

  2019cites this paper
• Inpatient Management of Migraine.

  2019cites this paper
• Headaches in Pregnancy and Postpartum

  2019cites this paper
• The discovery and development of inhaled therapeutics for migraine

  2019cites this paper
• The Role of Magnesium in Pathophysiology and Migraine Treatment

  2019cites this paper
• Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials

  2019cites this paper
• CGRP in Animal Models of Migraine.

  2019cites this paper
• Cortical spreading depression as a site of origin for migraine: Role of CGRP

  2019cites this paper
• Future Therapies for Trigeminal Autonomic Cephalalgias: Cluster Headache and Related Conditions

  2019cites this paper
• Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults

  2019cites this paper
• Enhanced mindfulness based stress reduction (MBSR+) in episodic migraine: a randomized clinical trial with MRI outcomes

  2019cites this paper
• Problematic presentation and use of efficacy measures in current trials of CGRP monoclonal antibodies for episodic migraine prevention: A mini-review

  2019cites this paper
• Migraine Management—Standard Therapies and New Strategies

  2019cites this paper
• Erenumab — Empfehlungen für die Praxis

  2019cites this paper
• Divergent influences of the locus coeruleus on migraine pathophysiology

  2018cites this paper
• Evidence mounts for anti-CGRP treatment in cluster headache

  2018cites this paper
• Refining the Benefit/Risk Profile of Anti-Epileptic Drugs in Headache Disorders

  2018cites this paper
• Peripherally administered calcitonin gene–related peptide induces spontaneous pain in mice: implications for migraine

  2018cites this paper
• Cluster Headache and Calcitonin Gene-Related Peptide-More on Quantum Therapeutics in Headache Medicine.

  2018cites this paper
• Current Evidence on the Role of Epigenetic Mechanisms in Migraine: The Way Forward to Precision Medicine

  2018cites this paper
• Chronic Migraine: Epidemiology, Mechanisms, and Treatment

  2018cites this paper
• Liječenje migrenske glavobolje

  2018cites this paper